南京招聘

？ Oversee PV system to ensure the compliance with relevant regulations and common practices.

？ Build and update PV SOPs according to latest requests by regulations or Health Authorities.

？ Ensure appropriate PV agreements are in place with relevant business partners.

？ Response to Health Authorities and HCPs for urgent safety issues and drug safety concerns.

？ Perform ongoing review of emerging safety data from various sources and provide medical safety oversight in the context of medical review process.

？ Work with operation teams to develop and continuously maintain and improve effective systems to ensure single cases fulfill the requirements for signal detection.

？ Responsible for safety assessment activities and lead PV risk management local process.

？ Drug risk evaluation and solicited data signaling.

？ Ensure appropriate clinical safety risk communication and escalation to China Medical Director, EU QPPV and EU Vigilance Risk Management Team.

？ Liaise with internal and external experts/KOLs to obtain specialized medical expertise as appropriate.

？ Provide high quality and consistent input to support clinical development and life cycle management.

？ Perform effective due diligence activities as appropriate.

任职资格：

？ MD degree or equivalent (e.g., DO or MB) required.

？ Two years or more of clinical experience as well as at least 5 years of pharmacovigilance experience, or overall equivalent experience profile.

？ Appropriate experience with Regulatory Agency and KOL interactions.

？ Knowledge of relevant concepts in data management and systems, epidemiology and statistics.

？ Effectively communicates in written and spoken English.

？ Excellent analytical and problem solving skills.

Provide effective and relevant review of complex documents.

萌蒂（中国）制药有限公司（以下简称“萌蒂中国制药”）自1993年成立以来，始终专注于在疼痛领域的规范化治疗理念的推广和产品研发与生产。
萌蒂中国制药目前在华拥有1300多位员工，业务遍布300多个城市。在北京拥有设备先进、专业生产麻醉和精神类药品的工厂。
通过20多年的不懈努力，萌蒂中国制药已成为中国癌痛领域的领导者，并引领镇痛领域。
多年来，我们一直坚持为提高人类的生活质量和健康水平而奋斗，“健康生活，品质人生”是我们的企业愿景；关爱生命，回馈社会是我们的社会责任；创新的天赋，以患者为核心的理念以及企业家精神是我们血液中的 DNA。
2018年3月，由国家卫生健康委员会扶贫办指导，《健康报》社、中国人口福利基金会健康报公益基金主办，萌蒂中国制药支持的“康萌大病救助计划”公益项目在北京正式启动，成为社会力量参与健康扶贫、大病救助的典范。
未来，萌蒂中国制药将继续深耕疼痛管理领域，同时将业务进一步拓展至抗呕吐、移植与免疫治疗、肿瘤、呼吸系统、健康消费品等全新领域，不断提供创新的产品，积极履行企业社会责任，为实现“健康生活，品质人生”的企业愿景而不懈努力。